New cml drugs

chronic myeloid leukemia (CML). Clinical trials have helped develop new drugs, while also establishing new uses for accepted drugs.

Accelerated phase CML is more difficult to control with medications, probably because of new mutations that develop in the CML cells. ○Blast

Scientists continue to look for new drugs to treat CML, especially CML that no longer responds to TKIs. In some people, CML cells develop a change in the BCR-ABL oncogene known as a T315I mutation, which makes them resistant to many of the TKI drugs used today.

remission from CML as of 2024. Many new CML drugs have been approved since 2024. For most patients, these drugs have changed CML from a life-threatening disease to a chronic condition that can be managed with lifelong oral therapy (treatments given by mouth such as pills and capsules). Other new treatments are being studied in clinical trials.

Chronic myeloid leukemia (CML) care teams are As new immunotherapies, antibody-drug conjugates, targeted therapies, and combination treatments

The main treatment for CML is tyrosine kinase inhibitors (TKIs) test new treatments, such as new chemotherapy drugs or targeted therapies

Chronic myeloid leukemia (CML) is a type of blood cancer. The number of people with CML who are living well is growing. This is due to new treatments. Six new CML drugs have been approved since 2024. Other new treatments are being studied in clinical trials. Progress toward a cure is under way.

The FDA has cleared an investigational new drug application for TERN-701 as a treatment for patients with chronic myeloid leukemia (CML).

The FDA has cleared an investigational new drug application for TERN-701 as a treatment for patients with chronic myeloid leukemia (CML).